A nanobody discovery pipeline incorporating competition-based yeast surface display assays is optimized to isolate single-chain variable heavy chain-only antibody domains (VHHs or nanobodies) that bind human ACE2 and inhibit SARS-CoV-2 entry, showcasing their potential as broadly acting receptor-targeted biologics against pandemic-threat viruses.
It is demonstrated that nanobodies targeting the PLpro/ISG15 interface can achieve synergistic antiviral and immunomodulatory effects, providing a proof-of-concept for a novel therapeutic approach to combat SARS-CoV-2 and potentially other emerging coronaviruses.
Guo-Long Liu, Jian-Tao Chen, Fang Wu et al.· Journal of Virology· 0 citations
HRBD demonstrated potent and broad-spectrum inhibition against Pangolin-CoV, SARS-CoV, SARS-CoV, SARS-CoV-2, and its variants, lowering the half-maximal inhibitory concentration (IC50) by approximately 1000-fold compared to the monomeric RBD.
Jintao Zou, Lingyu Su, Jian-Sheng Lu et al.· Antiviral Research· 0 citations
These findings show that minimal, structure-guided epitope remodeling can enhance the presentation of conserved epitopes and improve antibody breadth, providing a generalizable framework for designing vaccines resilient to viral evolution and future pandemic threats.
A. Odainic, Ioannis Vardaxis, M. Ferraz et al.· Frontiers in Immunology· 0 citations
The results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoCs in vitro, ex vivo, and in vivo.
Esteban M. Castro, Ramya S. Barre, C. Ye et al.· bioRxiv· 0 citations
The results show the value of nanobody technology for identifying novel neutralising epitopes in the S2 region of beta-coronaviruses with potential for the development of new selective anti-viral agents.
John D. Clarke, Luke M. Jones, Imogen I. H. Buckle et al.· Scientific Reports· 0 citations
It is shown that plasma IgG reactivity to this region remains rare, even after repeated antigen exposure, and kinetic and avidity constraints governing neutralization at the HR2 stem helix and position hr2.016 as a resilient therapeutic candidate.
Virginia Crivelli, Concetta Guerra, M. Abernathy et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.